Recognised as a Rising Star Partner by IFLR since 2022.
Ranked on the Up-and-Coming List on Corporate M&A section by Chambers in 2023.

Bar Admissions
Member of the Taipei Bar Association
Member of the New York State Bar Association

Education
LL.M., Harvard University
LL.B., National Taiwan University
B.B.A. (Finance), National Taiwan University

Professional Activities and Experience
- Representation of TXOne Network in its multi-series preferred shares fund raising and corporate restructuring
- Representation of Bora Pharmaceutical in the US$50M acquisition of Eden Biologics' CDMO businesses and US$195M acquisition of 100 equity stake of TWi Pharmaceuticals
- Representation of MagiCapital in the US$138M acquisition of Ili Technology (a 100 subsidiary of MediaTek)
- Representation of Quaser Group (a Taiwan listed company) of its acquisition of Winbro Group (a US and UK company in aerospace industry) and obtain US CFIUS approval
- Representation of TPG Group's acquisition of OPC Group (the top one CRO company in Taiwan)
- Representation of Guangdong Fenghua Advanced Technology (a Shenzhen listed company) in its tender offer of Viking Tech. (First tender offer deal of a Taiwan listed company by a PRC investor.)
- Representation of CID -led consortium in its tender offer and merger of Entire Technology and APEC (both are Taiwan listed companies).
- Representation of Bora Pharmaceutical's acquisition of 100 shareholding in Impax Laboratories (a subsidiary of US Impax group) and various investment projects
Representation of JEAN Group (a Taiwan listed company) in its asset sale to BOE Group (a Chinese SOE)
- Representation of Novartis in its transaction with GlaxoSmithKline ("GSK") in the sale of Novartis' non-influenza Vaccines business and acquisition of GSK's oncology portfolio
- Representation of overseas Taiwanese investment in acquisition of targets in Europe, America and Asia
Offshore PE fund formation in the form of limited partnership and segregated portfolio company (AI, real property, manufacturing, IOT industry and etc.) and subsequent fund investment
Taiwan PE fund formation in the form of closed-end company and limited partnership (biotech, pharmaceutical, manufacturing, IT semiconductor, energy and etc.) and subsequent fund investment
- Representation of Venture Capital companies in their investment and disposal of portfolio companies
- Representation of pharmaceutical companies and biotech companies in their clinical trial, OEM, license agreement and co-development of pharmaceutical products with various business partners
- Representation of foreign investors and domestic private equity firms in the formation of energy funds and subsequent investments in solar energy projects
- Representation of IPO projects in Hong Kong Stock Exchange, Shanghai Stock Exchange and Taiwan Stock Exchange